Anzeige
Mehr »
Samstag, 14.02.2026 - Börsentäglich über 12.000 News
Die Kommerzialisierung der räumlichen Intelligenz in Billionen-Märkten beginnt jetzt
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
35 Leser
Artikel bewerten:
(0)

Luminex to Host MAGPIX Road Shows Throughout the U.S. and Europe

AUSTIN, Texas, September 28, 2010 /PRNewswire/ --

- MULTINATIONAL TOUR TO SHOWCASE CAPABILITIES OF NEW MULTIPLEXING INSTRUMENT

Luminex Corporation (Nasdaq: LMNX), today announced the initial dates and locations for the MAGPIX(R) road show, a multinational tour designed to showcase the recently-launched MAGPIX analytical instrument that is capable of performing up to 50 tests on a single sample and providing nearly 5,000 data points in under an hour. The innovative format of the tour lets users interact directly with the system and each other to enhance the sharing of a broad set of applications.

(Logo: http://photos.prnewswire.com/prnh/20100104/LUMINEXLOGO) (Logo: http://www.newscom.com/cgi-bin/prnh/20100104/LUMINEXLOGO)

"We are very excited to launch our MAGPIX road show series to allow researchers around the world to experience MAGPIX first hand," said Patrick J. Balthrop, president and chief executive officer of Luminex. "This is an opportunity for scientists across many disciplines to see, in person, how MAGPIX easily allows them to harness the power of multiplexing and advance their research."

The MAGPIX road show events will feature a presentation from a MAGPIX user as well as an overview of the instrument and an explanatory animation of the technology. EMD Millipore, the first distributor of the MAGPIX instrument worldwide, also will be on site for demonstrations and to answer questions at the U.S. events.

The following dates and locations have been scheduled for the MAGPIX road show in Europe:

September 13 - Luminex Europe Office, Oosterhout, The Netherlands September 15 - Wageningen University, Wageningen, The Netherlands September 28 - October 1 - Exhibiting at The Instrument, The Sounds of Technology Conference, Amsterdam, The Netherlands October 5 - 7 - Exhibiting at the Biotechnica Conference, Hanover, Germany October 20-21 - Luminex Planet xMAP Multiplexing Congress, Vienna, Austria

The following dates and locations have been scheduled for the MAGPIX road show in the U.S.:

November 2 - Longwood Galleria, Boston, MA November 3 - Middlesex Lounge, Cambridge, MA November 11 - The Bentley Reserve, San Francisco, CA November 13 - University Club, San Diego, CA, in conjunction with the Society for Neuroscience Annual Meeting December 13 - The Mask and Wig, Philadelphia, PA, in conjunction with the American Society for Cell Biology Annual Meeting

For more information on the entire MAGPIX road show, visit http://www.luminexcorp.com/magpix.

Based on Luminex's xMAP(R) Technology, the easy-to-use MAGPIX instrument is compact - comparable in size to a desktop computer - making it attractive to smaller and lower-volume laboratories and institutions with limited resources and bench space. The instrument provides fast, accurate and easily reproducible results and can advance research across many disease states by bringing many types of multiplexing applications to scientists. MAGPIX is easy to install out of the box and weighs less than 40 lbs., approximately 18 kg, making it simple and affordable to ship and deploy anywhere in the world. The instrument was designed to meet the needs of scientists who have not been able to take advantage of the power of multiplexing because of resource or space limitations.

For more information on MAGPIX, call +1-512-219-8020, or visit http://www.luminexcorp.com/magpix.

About Luminex Corporation

Luminex Corporation develops, manufactures and markets proprietary biological testing technologies with applications throughout the diagnostic and life sciences industries. The Company's xMAP(R) multiplex solutions include an open-architecture, multi-analyte technology platform that delivers fast, accurate and cost-effective bioassay results to markets as diverse as pharmaceutical drug discovery, clinical diagnostics and biomedical research, including the genomics and proteomics markets. The Company's xMAP Technology is sold worldwide and is already in use in leading clinical laboratories as well as major pharmaceutical, diagnostic and biotechnology companies. Further information on Luminex Corporation or xMAP Technology can be obtained at http://www.luminexcorp.com.

Luminex Corporate Contact: Harriss T. Currie, Vice President, Finance and Chief Financial Officer +1-512-219-8020 hcurrie@luminexcorp.com Matthew Scalo Sr. Director of Investor Relations +1-512-219-8020 mscalo@luminexcorp.com Luminex Media Contact: Nicole Cottrill +1-615-327-7999 ncottrill@seigenthaler.com

Luminex Corporation

Corporate, Harriss T. Currie, Vice President, Finance and Chief Financial Officer, hcurrie@luminexcorp.com, or Matthew Scalo, Sr. Director of Investor Relations, mscalo@luminexcorp.com, both of Luminex Corporation, +1-512-219-8020; or Media, Nicole Cottrill, +1-615-327-7999, ncottrill@seigenthaler.com, for Luminex Corporation

© 2010 PR Newswire
Favoritenwechsel - diese 5 Werte sollten Anleger im Depot haben!
Das Börsenjahr 2026 ist für viele Anleger ernüchternd gestartet. Tech-Werte straucheln, der Nasdaq 100 tritt auf der Stelle und ausgerechnet alte Favoriten wie Microsoft und SAP rutschen zweistellig ab. KI ist plötzlich kein Rückenwind mehr, sondern ein Belastungsfaktor, weil Investoren beginnen, die finanzielle Nachhaltigkeit zu hinterfragen.

Gleichzeitig vollzieht sich an der Wall Street ein lautloser Favoritenwechsel. Während viele auf Wachstum setzen, feiern Value-Titel mit verlässlichen Cashflows ihr Comeback: Telekommunikation, Industrie, Energie, Pharma – die „Cashmaschinen“ der Realwirtschaft verdrängen hoch bewertete Hoffnungsträger.

In unserem aktuellen Spezialreport stellen wir fünf Aktien vor, die genau in dieses neue Marktbild passen: solide, günstig bewertet und mit attraktiver Dividende. Werte, die nicht nur laufende Erträge liefern, sondern auch bei Marktkorrekturen Sicherheit bieten.

Jetzt den kostenlosen Report sichern – bevor der Value-Zug 2026 endgültig abfährt!

Dieses exklusive PDF ist nur für kurze Zeit gratis verfügbar.
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.